Harley-Davidson Inc vs Johnson & Johnson — how do they compare? Harley-Davidson Inc trades at $26.75 (market cap $2.78B), while Johnson & Johnson trades at $256.12 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 222.3× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays the higher dividend (2.8%). Which is the better fit depends on your goals — on Pluang, investors hold Harley-Davidson Inc for 91 Days and Johnson & Johnson for 129 Days on average.
| HOG | JNJ | |
|---|---|---|
Market Cap | $2.78B | $618.09B |
Volume | 2,966,389 | 6,050,983 |
Sector | Consumer Cyclical | Health |
52-Week High | $28.46 | $278.43 |
52-Week Low | $17.19 | $186.00 |
Typical Hold Time | 91 Days | 129 Days |
Enterprise Value | $3.20B | $646.37B |
Dividend Yield | 2.8% | 2.09% |
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $26.95, up 0.04% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $28.50. Recent Q2 2026 earnings beat expectations, but revenue has declined from $5.8B in 2022 to $4.5B in 2025, with net income margin falling to 7.57%. The company maintains a dividend and shows improved cash flow trends, though it faces headwinds from tariffs and a recent data breach investigation.
The stock presents a mixed outlook: valuation metrics like P/E of 14.97 and P/B of 0.9 suggest potential upside, but declining profitability and competitive pressures pose risks. Investor sentiment is cautious with 61% hold ratings, while institutional activity shows mixed positioning. Key catalysts include execution of the 'Back to the Bricks' strategy, though tariff exposures and softening demand remain concerns.
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →